Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

1.2K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.2K
Urinary Bladder01:23

Urinary Bladder

4.2K
The urinary bladder is a hollow, muscular sac that temporarily stores urine before it is expelled from the body. It can hold approximately 600 mL of urine prior to micturition. The bladder is retroperitoneal and located behind the pubic symphysis in the pelvic floor.
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
4.2K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

869
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
869
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

322
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
322
Urodynamic Studies: Uroflowmetry01:19

Urodynamic Studies: Uroflowmetry

7.4K
Uroflowmetry is a non-invasive urodynamic test designed to measure various aspects of urination, including volume, flow rate, and the time to void. This test is crucial for diagnosing and assessing conditions such as bladder outlet obstruction, bladder dysfunction, incomplete bladder emptying, incontinence, and urinary tract blockages caused by benign prostatic hyperplasia (BPH) and urethral strictures.Pre-Test Instructions:Before a uroflowmetry test, patients are typically advised to drink...
7.4K
Urinary Tract Calculi V: Nursing Management01:28

Urinary Tract Calculi V: Nursing Management

419
AssessmentSubjective Data: Obtain a detailed health history, including any recent or chronic urinary tract infections, periods of immobilization, previous episodes of renal calculi, and medical conditions such as gout, benign prostatic hyperplasia, or hyperparathyroidism. Review the medication history for drugs that may influence stone formation, including allopurinol, analgesics, loop diuretics, or thiazide diuretics. Document the use of long-term indwelling catheters and any past surgical...
419

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The genitourinary phenotype of COVID: a personal perspective.

International urology and nephrology·2026
Same author

Senescence-Driven Inflammation and Immune Dynamics in the Progression of Radiation Cystitis.

Cells·2026
Same author

Safety and Efficacy of LP-10 Liposomal Tacrolimus in Oral Lichen Planus: A Multicenter Phase 2 Trial.

Dermatology and therapy·2025
Same author

Advancing Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) Diagnosis: A Comparative Analysis of Machine Learning Methodologies.

Diagnostics (Basel, Switzerland)·2024
Same author

Rationale for the Use of Topical Calcineurin Inhibitors in the Management of Oral Lichen Planus and Mucosal Inflammatory Diseases.

Cureus·2024
Same author

Iltamiocel Autologous Cell Therapy for the Treatment of Female Stress Urinary Incontinence: A Double-Blind, Randomized, Stratified, Placebo-Controlled Trial.

Neurourology and urodynamics·2024

Related Experiment Video

Updated: Mar 28, 2026

Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

2.4K

Statin-Associated Underactive Bladder.

Teruhiko Yokoyama1, Michael B Chancellor2

  • 1Department of Urology, Kawasaki Medical School, Kurashiki, Japan.

Lower Urinary Tract Symptoms
|December 15, 2015
PubMed
Summary

Statins, used for high cholesterol, may cause permanent urinary retention. A case study suggests statin-induced bladder damage, potentially leading to underactive bladder and retention issues.

Keywords:
bladderstatinunderactive bladderurinary retention

More Related Videos

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

27.0K
Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice
11:46

Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice

Published on: April 27, 2014

18.5K

Related Experiment Videos

Last Updated: Mar 28, 2026

Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

2.4K
Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

27.0K
Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice
11:46

Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice

Published on: April 27, 2014

18.5K

Area of Science:

  • Pharmacology
  • Urology

Background:

  • Statins are commonly prescribed lipid-lowering drugs.
  • Adverse effects of statins are a significant clinical concern.
  • Urinary retention is a potential, though rare, side effect.

Purpose of the Study:

  • To report a case of statin-associated permanent urinary retention.
  • To investigate the potential link between statin use and bladder dysfunction.

Main Methods:

  • A case report of a 69-year-old woman experiencing urinary retention.
  • Analysis of medication history, focusing on statin use (Cerivastatin).
  • Observation of symptom changes following statin discontinuation.

Main Results:

  • The patient developed urinary retention after two months of oral Cerivastatin.
  • Discontinuation of Cerivastatin led to a modest improvement in urinary retention symptoms.
  • This suggests a possible causal relationship between the statin and the urinary retention.

Conclusions:

  • This case highlights a potential risk of permanent bladder smooth muscle damage from statin use.
  • Statin-induced bladder damage may contribute to the development of underactive bladder and urinary retention.
  • Further research is warranted to confirm the association and elucidate the mechanism.